Efficacy
Given heterogeneity was observed in each efficacy analysis, the
random-effects model was employed to calculate the pooled outcomes. The
ORR of all 8 studies ranged from 6% to 43%. The pooled ORR was 29%
(95% CI: 20%-38%) and there was considerable heterogeneity in the
results (I2=84.5%, p =0.000) (Figure 3A). Six
studies reported DCR, which ranged from 42% to 86%. The pooled DCR was
71% (95% CI: 56%-86%) and significant heterogeneity was identified
in the DCR analysis (I2=93.1%, p =0.000)
(Figure 3B).
Although OS data were reported in seven studies, the results ofZhang 2022 and cohort 1 in Yamaguchi 2023 were not
included in the analysis because they did not reach the upper confidence
interval. The mOS of the other 6 studies ranged from 7.90 to 12.80
months, the pooled result was 9.68 months (95% CI: 7.78-11.58 months),
and the heterogeneity in the mOS analysis was moderate
(I2=71.1%, p=0.004) (Figure 3C). PFS data were
available in all 8 studies and the results of the two cohorts inYamaguchi 2023 were analyzed and presented separately. The mPFS
of the studies ranged from 2.70 to 5.60 months and the pooled result was
4.06 months (95% CI: 3.22-4.90 months). The mPFS analysis indicated
moderate heterogeneity (I2=73.3%, p =0.000)
(Figure 3D). To sum up, HER2-targeted ADCs could induce tumor response
and bring survival benefits for GC/GEJC patients.